据港交所1月30日披露，明智科技股份有限公司(简称：明智科技)向港交所主板递交上市申请，建银国际为其独家保荐人。招股书显示，根据灼识咨询的资 料，按2024年出货量计算，明智科技位列美国、欧洲及日本一次性输尿管镜市场前三大品牌。此外，该公司开发了世界上最纤细之一的一次性输尿管镜，及 世界上最纤细之一的膀胱镜(工作通道为6.6Fr)。 公司简介 据招股书，明智科技是一家平台型医疗器械公司，凭借创新可视化与微创医疗器械，在一次性泌尿科内窥镜领域处于领先地位。该公司于硅谷及中国营运， 专注于一次性内窥镜系统的研发和商业化。明智科技是全球极少数成功实现一次性内窥镜供应链垂直整合的公司之一，涵盖从核心光电组件及精密零件的自 主研发制造，到完整系统的组装全过程。 凭借明智科技的自有品牌组合-包括OTU(ONETU )、与顶尖医疗科技公司共同打造的OTU联合品牌，以及WiScope —该公司已开发覆盖泌尿科、肝胆外科、 呼吸科、耳鼻喉科、肠胃科及妇科的全面产品组合。截至最后实际可行日期，明智科技在全球主要市场(包括美国、欧盟及中国)拥有8个已获批产品类别以 及5个在研产品类别。 明智科技的产品组合包括两个主要部分： 1.一 ...

智通财经APP获悉，据港交所1月30日披露，明智科技股份有限公司(简称：明智科技)向港交所主板递交上市申请，建银国际为其独家保荐人。招股书显示， 根据灼识咨询的资料，按2024年出货量计算，明智科技位列美国、欧洲及日本一次性输尿管镜市场前三大品牌。此外，该公司开发了世界上最纤细之一的一 次性输尿管镜，及世界上最纤细之一的膀胱镜(工作通道为6.6Fr)。 公司简介 据招股书，明智科技是一家平台型医疗器械公司，凭借创新可视化与微创医疗器械，在一次性泌尿科内窥镜领域处于领先地位。该公司于硅谷及中国营运， 专注于一次性内窥镜系统的研发和商业化。明智科技是全球极少数成功实现一次性内窥镜供应链垂直整合的公司之一，涵盖从核心光电组件及精密零件的自 主研发制造，到完整系统的组装全过程。 凭借明智科技的自有品牌组合-包括OTU(ONETU)、与顶尖医疗科技公司共同打造的OTU联合品牌，以及WiScope该公司已开发覆盖泌尿科、肝胆外科、呼 吸科、耳鼻喉科、肠胃科及妇科的全面产品组合。截至最后实际可行日期，明智科技在全球主要市场(包括美国、欧盟及中国)拥有8个已获批产品类别以及5 个在研产品类别。 2.图像处理器：兼容资本设备( ...

Core Viewpoint - Ambu's aScope 5 Cysto HD has received FDA approval for use in percutaneous nephrolithotomy (PCNL), marking a significant advancement in the application of disposable endoscopes in complex urological surgeries, enhancing the platform's capabilities in minimally invasive procedures [2][15]. Product Development and Features - The aScope 5 Cysto HD is a high-resolution, bidirectional flexible endoscope designed initially for bladder examinations and ureteral observations, now expanded to include kidney stone surgeries [3][14]. - The endoscope has a diameter between 4.8 to 5.4 mm, with a tip deflection of up to 210°, and features a CMOS image sensor supporting 1080p HD imaging, providing superior visualization in complex anatomical areas [5][15]. - The single-use nature of the aScope 5 Cysto HD significantly reduces the risk of cross-contamination and simplifies the preparation and cleaning processes compared to traditional reusable endoscopes [5][15]. Clinical Application and Advantages - In PCNL procedures, the aScope 5 Cysto HD can assist in stone localization, enhance stone fragmentation efficiency, and confirm the absence of residual stones post-surgery [10][11]. - The system supports dual visualization by integrating with Ambu's aScope 5 Uretero, allowing simultaneous display and control of two endoscopes, which saves time and reduces anesthesia exposure during surgery [9][10]. Market Position and Strategy - Ambu holds over 50% market share in the global disposable endoscope market, with its aScope series utilized in over 8,000 medical institutions [12]. - The company’s strategy focuses on a "procedure-oriented + platform synergy" approach, differentiating itself from traditional reusable endoscope manufacturers [12][16]. Future Outlook - Ambu plans to initiate larger-scale clinical trials in 2026 to further validate the aScope 5 Cysto HD's adaptability and long-term efficacy across various patient demographics and surgical complexities [13]. - The company is also exploring the expansion of its aScope platform into gastroenterology and respiratory fields, aiming for multidisciplinary collaboration and integration of advanced features like 4K imaging and AI navigation [13][16].